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The Gly388Arg polymorphism in the fibroblast growth factor receptor 4 (FGFR4) gene has been reported to influence prognosis in a
wide variety of cancer types. To determine whether Gly388Arg is a marker for lung cancer prognosis, we genotyped 619 lung cancer
patients with incident disease and examined the relationship between genotype and overall survival. While we employed a
comprehensive set of statistical tests, including those sensitive to the detection of differences in early survival, our data provide little
evidence to support the tenet that the FGFR4 Gly388Arg polymorphism is a clinically useful marker for lung cancer prognosis.
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Lung cancer remains a leading cause of cancer death worldwide
(Parkin et al, 2005). Despite recent improvements in treatment, the
prognosis has only marginally improved and 5-year survival rates
from both small-(SCLC) and non-small-cell lung cancer (NSCLC)
are generally no better than 15% (Cancer Research UK). While the
major prognostic determinant is stage at presentation, there is
variability in survival for patients with same-stage disease, making
it highly advantageous to identify further prognostic markers,
which may predict patients likely to benefit from treatment.
Furthermore, detecting genes with prognostic relevance has the
potential to aid the identification of pathways that may be targeted
for therapeutic interventions.
The FGF/FGFR receptor (FGFR) signalling pathway plays a
pivotal role in cellular biology, being involved in differentiation,
angiogenesis and motility (reviewed in Powers et al (2000)).
Dysregulation of this pathway is a feature of a number of tumours
and allelic imbalance at several FGF/FGFR loci is common in lung
cancer. Correlations between such changes and lymph node status
in cancer has been reported (Beau-Faller et al, 2003), implying that
FGF/FGFR signalling may play an important role in the growth and
survival of cancer cells.
A specific role for FGFR4 in cancer is not well established, but
altered expression has been documented in breast, lung, pancreatic
and prostate cancers (Bange et al, 2002; Shah et al, 2002;
Nakamura et al, 2004; Wang et al, 2004). Recently, a common
polymorphism in the transmembrane domain of the FGFR4 gene,
Gly388Arg, has been reported to correlate with tumour aggres-
siveness (lymph node metastasis, advanced stage at presentation
and reduced survival in several cancer types, including breast,
sarcoma, lung and prostate (Bange et al, 2002; Morimoto et al,
2003; Nakamura et al, 2004; Wang et al, 2004; Spinola et al,
2005a)). Some of these studies were, however, conducted on
relatively small sample sizes and subsequent studies of breast,
colon, head and neck, and bladder cancers (Becker et al, 2003;
Jezequel et al, 2004; Streit et al, 2004; Spinola et al, 2005b; Yang
et al, 2006), have provided little support for an association between
FGFR4 Gly388Arg genotype and prognosis.
To evaluate the prognostic significance of the FGFR4 Gly388Arg
polymorphism in lung cancer, we analysed a cohort of 619 lung
cancer patients. We employed a comprehensive set of statistical
tests, including those sensitive to detecting differences in early
survival.
MATERIALS AND METHODS
Patients
Patients with lung cancer were ascertained through the Genetic
Lung Cancer Predisposition Study (GELCAPS), a population-based
study of lung cancer. Further details about the design and conduct
of the study are described in previously published material
(Matakidou et al, 2005). The current analysis is based on 619
female patients from whom detailed clinicopathological data and
follow-up information on patients had been collected using a
standardised proforma. All cases in this current analysis are white
Caucasians who lived in the United Kingdom at the time of sample
acquisition. The clinicopathologic characteristics of the patients
are detailed in Table 1. DNA was extracted from EDTA-venous
blood samples by a salt extraction procedure and quantified by
Picogreen (Invitrogen, Paisley, UK). Genotyping was conducted by
means of Illumina Sentrix Bead Arrays (Illumina, San Diego, CA,
USA) according to the manufacturer’s protocols (details available
on request). Ethical approval for the study was obtained from the
London Multi-Centre Research Ethics Committee (MREC/98/2/67)
in accordance with the tenets of the Declaration of Helsinki. All
participants provided informed consent.
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Statistical analyses were undertaken using S-Plus (Version 8,
Insightful Corporation, Seattle, WA, USA). We tested for
Hardy–Weinberg equilibrium using an exact test based on
genotypic frequencies. Overall survival (OS) of patients was the
end point of the analysis. Survival time was calculated from
the date of diagnosis of lung cancer to the date of death. Patients
who were not deceased were censored at the date of last contact.
Mean follow-up time was computed among censored observations
only. Kaplan–Meier survival curves according to genotype
were generated and the homogeneity of the survival curves
between genotypes was evaluated using the log-rank, and
Wilcoxon and Fleming–Harrington tests (with r set to 0, 1 and
 1 within the S-Plus servdiff function for each of the tests
respectively) (Klein and Moeschberger, 1997). The log-rank test is
usually the preferred test, but the other tests were conducted to
show the influence of the polymorphic variation at different
times of follow-up in order to detect any difference in early and
late stages of disease (Klein and Moeschberger, 1997). Cox
regression analysis (Klein and Moeschberger, 1997) was used to
estimate hazard ratios (HRs) and their 95% confidence intervals
(CI), while adjusting for age, smoking, treatment, histology
and stage.
RESULTS
One hundred and fifty-four of the total number of patients (25%)
had SCLC, less than half (43%) presenting with limited disease. Of
the 465 patients with NSCLC, 57 (13%) had stage I, 68 (15%) had
stage II, 196 (43%) had stage III and 130 (29%) had stage IV
disease at diagnosis. The majority of patients with limited-stage
SCLC had been treated with a combination of radical radiotherapy
and chemotherapy, while all patients received chemotherapy
(Table 1). The main treatment modality for SCLC patients with
extensive disease was chemotherapy. Patients with early-stage
NSCLC (stage I and II disease) were mainly treated with surgical
resection of the primary tumour, while about one-third received
chemotherapy and radical radiotherapy. The mainstay treatment
modality of patients with stage III and IV NSCLC was chemother-
apy. The mean follow-up time for patients alive at end of follow-up
was 21.0 months (range 0–60.5 months). There were 389 (62.8%)
deaths in the entire cohort. For all patients, the median survival
time (MST) was 16.2 months. Patients with SCLC had an MST of
17.8 and 11.1 months, if diagnosed with limited and extensive
disease, respectively. For NSCLC, by stage, MST ranged from 11.5
months in stage IV patients to 49.2 months in the stage I group. As
these survival rates are not significantly different to those
documented in previously published audits of lung cancer
prognosis, there is no evidence that ‘healthy study participant’
selection will have biased our analyses.
Surgery, any chemotherapy and treatment specifically with
platinum-based compounds did not satisfy the proportional
hazards assumption required for the Cox model. Therefore, we
used a stratified Cox proportional hazards model, stratifying on
surgery, platinum, chemotherapy and surgery. As expected, factors
significantly influencing patient prognosis were stage at presenta-
tion (Po10
 4), histology (P¼0.026) and radiotherapy
(P¼0.0042). Smoking, family history of lung cancer and age at
diagnosis did not impact on survival.
Genotyping of the Gly388Arg polymorphism in all patients
showed 319 (51.5%) were homozygous Gly/Gly alleles, 252 were
heterozygous for the Gly/Arg alleles (40.7%) and 48 (7.8%)
homozygous for the Arg/Arg alleles. There was no evidence in
the data set indicative of Hardy–Weinberg disequilibrium
(P¼0.92). There was no correlation between FGFR4 SNP genotype
and the pathological parameters, stage (P¼0.58) and histology
(P¼0.94). Figure 1 shows Kaplan–Meier survival analysis by
genotype. All non-parametric tests provided no evidence for a
relationship between SNP genotype and OS (P-values 0.555, 0.751
and 0.347 for log rank, Wilcoxon and Fleming–Harrington test
statistics, respectively). Under the Cox proportional hazards
model, the HRs for Arg/Gly heterozogosity, Arg/Arg homozygosity
and Arg-carrier status were: 0.95 (95% CI: 0.77–1.18), 1.06 (95%
CI: 0.72–1.56) and 0.97 (95% CI: 0.79–1.19), respectively. A
stratified analysis based on individual histological groupings also
provided no evidence that SNP genotype influenced OS (Table 2).
DISCUSSION
We have found no evidence of an association between FGFR4
Gly388Arg genotype and lung cancer pathological parameters.
Furthermore, our findings do not indicate that the FGFR4
genotype is an independent predictor of prognosis for lung cancer.
Stratification by histological subtype did not impact on the
significance of these results. Our observations are in contrast with
those reported by Spinola et al (2005a), supporting a correlation
between FGFR4 genotype and lung cancer prognostic variables in
patients with adenocarcinomas.
The major strengths of our study are its large size, the fact that it
is population based on patients with incident disease and that it
has involved the systematic follow-up of patients. Even though bias
from non-uniform treatment is a potential confounder in studies
Table 1 Demographic and follow-up characteristics of patients
Number of patients (%)
Total 619
Mean age (years) 64.8
Smoking habits
Non-smokers 49 (8)
Smokers 570 (92)
Histology
Small cell (SCLC) 154 (25)
Non-small cell (NSCLC) 465 (75)
Squamous 180 (30)
Adenocarcinoma 164 (27)
Tumour stage (by histology)
SCLC
Limited 66 (43)
Extensive 86 (57)
NSCLC
I 57 (13)
II 68 (15)
III 196 (43)
IV 130 (29)
Median survival time (months) 16.2
Events (deaths) 389 (62.8)
Median survival time, months, by histology and stage
SCLC
Limited 17.8
Extensive 11.1
All stages 13.5
NSCLC
I 49.2
II 31.9
III 16.2
IV 11.5
All stages 17.6
NSCLC¼non-small-cell lung cancer; SCLC¼small-cell lung cancer.
FGFR4 Gly388Arg polymorphism and lung cancer prognosis
A Matakidou et al
1905
British Journal of Cancer (2007) 96(12), 1904–1907 & 2007 Cancer Research UK
M
o
l
e
c
u
l
a
r
D
i
a
g
n
o
s
t
i
c
sof some solid tumours, the management of lung cancer is relatively
uniform in the United Kingdom, as there are only a restricted
number of effective chemotherapeutic agents and prognosis is
uniformly poor. Support for this assertion is provided by the fact
that the survival rates observed in our patient cohort were not
different to those expected. It is therefore unlikely that any
spurious influence as a consequence of study design will have
impacted significantly on findings. As our analysis was restricted
to white patients and there was no statistical evidence for
population substructure, findings are unlikely to be confounded
by this form of potential bias.
Our study does not support the findings of Spinola et al (2005a).
This could in part be a consequence of differences in study design.
Our study included a higher proportion of patients with late-stage
disease, with consequent shorter follow-up time and potential
reduced power to demonstrate a relationship. Furthermore, our
analysis was not restricted to adenocarcinoma cases. Accepting
this caveat, we did not find evidence of a relationship between
prognosis and FGFR4 genotype for any of the lung cancer
histology.
The notion that germline variation in FGFR4 may influence
biology of tumours is an attractive postulate. The reason for the
conflicting results between studies that have evaluated the role of
Gly388Arg is not entirely obvious. Some differences may reflect
tissue-specific effects of this polymorphism. It is, however, not
uncommon for the first published studies to report over-inflated
estimates of effects, which subsequent larger studies cannot
replicate. Studies that have examined the role of FGFR4 in the
carcinogenesis provide evidence for the complexity of the FGF/
FGFR signalling pathway in different tumour types (Olson et al,
1998; Cavallaro et al, 2001; Ezzat et al, 2002; Shah et al, 2002). It
therefore seems unlikely a priori that a single SNP, albeit one with
functional effects, will impart substantial differences in cancer
prognosis independently. In conclusion, we believe there is
currently little evidence to suggest that the Gly388Arg polymorph-
ism of FGFR4 represents a robust marker of lung cancer prognosis.
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Figure 1 Kaplan–Meier curves for all lung cancer patients. Survival
curves for the Gly/Gly homozygotes are shown as a solid line. The dashed
line depicts the survival curve for the Gly/Arg heterozygotes, and the
broken line depicts the survival curve for the rare homozygotes Arg/Arg.
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